A recent study showed that RBCMs can successfully target the transferrin receptor at the blood-brain barrier and glioma surface, as well as CD13 that is highly expressed by tumor cells, through the dual modification of T7 peptide and polypeptide NGR, and significantly enhance the anti-glioma effect [226]. The gene discussed is RTN4R; the disease is glioma.